Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P08779
UPID:
K1C16_HUMAN
Alternative names:
Cytokeratin-16; Keratin-16
Alternative UPACC:
P08779; A8K488; P30654; Q16402; Q9UBG8
Background:
Keratin, type I cytoskeletal 16, also known as Cytokeratin-16 or Keratin-16, is an epidermis-specific type I keratin crucial for skin integrity. It plays a pivotal role in skin, acting as a regulator of innate immunity in response to skin barrier breach. This protein is essential for the maintenance of skin barrier and inflammatory checkpoints.
Therapeutic significance:
Keratin-16 is linked to Pachyonychia congenita 1 and Keratoderma, palmoplantar, non-epidermolytic, focal 1, diseases characterized by skin abnormalities. Understanding the role of Keratin-16 could open doors to potential therapeutic strategies for these dermatological disorders.